Toward an Optimal Joint Recognition of the S1‘ Subsites of Endothelin Converting Enzyme-1 (ECE-1), Angiotensin Converting Enzyme (ACE), and Neutral Endopeptidase (NEP)

Journal of Medicinal Chemistry
2002.0

Abstract

The formation of vasoconstrictors (e.g., angiotensin II and endothelin) and the inactivation of vasodilators (e.g., bradykinin and atrial natriuretic) by membrane-bound zinc metallopeptidases are key mechanisms in the control of blood pressure and fluid homeostasis. The way in which these peptides modulate physiological functions has been intensively studied. With the aim to develop compounds that can jointly block the three metallopeptidases-neutral endopeptidase (NEP, neprilysin), angiotensin-converting enzyme (ACE), and endothelin-converting enzyme (ECE-1)-we studied the common structural specificity of the S1' subsites of these peptidases. Various mercaptoacyl amino acids of the general formula HS-CH2-CH(R1')CO-Trp-OH, possessing more or less constrained R1' side chains, were designed. The mercapto-acyl synthons contain one or two asymmetrical centers. The K(i) values of the separated stereoisomers of the most efficient inhibitors were used to determine the stereochemical preference of each enzyme. A guideline for the joint inhibition of the three peptidases was obtained with the (2R,3R) isomer of compound 13b. Its K(i) values on NEP, ACE, and ECE were 0.7, 43, and 26 nM, respectively.

Knowledge Graph

Similar Paper

Toward an Optimal Joint Recognition of the S<sub>1</sub>‘ Subsites of Endothelin Converting Enzyme-1 (ECE-1), Angiotensin Converting Enzyme (ACE), and Neutral Endopeptidase (NEP)
Journal of Medicinal Chemistry 2002.0
Optimal Recognition of Neutral Endopeptidase and Angiotensin-Converting Enzyme Active Sites by Mercaptoacyldipeptides as a Means To Design Potent Dual Inhibitors
Journal of Medicinal Chemistry 1996.0
Mercaptoacyl dipeptides as dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Preliminary structure-activity studies
Bioorganic &amp; Medicinal Chemistry Letters 1994.0
New .alpha.-Thiol Dipeptide Dual Inhibitors of Angiotensin-I-Converting Enzyme and Neutral Endopeptidase EC 3.4.24.11
Journal of Medicinal Chemistry 1995.0
Phosphinic Tripeptides as Dual Angiotensin-Converting Enzyme C-Domain and Endothelin-Converting Enzyme-1 Inhibitors
Journal of Medicinal Chemistry 2010.0
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme
Journal of Medicinal Chemistry 2020.0
Lucilactaene, a New Cell Cycle Inhibitor in p53-Transfected Cancer Cells, Produced by a Fusarium sp.
The Journal of Antibiotics 2001.0
Mercaptoacyl Dipeptides as Orally Active Dual Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase
Journal of Medicinal Chemistry 1996.0
Design and Synthesis of Potent, Selective Inhibitors of Endothelin-Converting Enzyme
Journal of Medicinal Chemistry 1998.0
Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2009.0